Enavate Sciences GP LLC acquired a new position in Upstream Bio, Inc. (NASDAQ:UPB - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 2,459,703 shares of the company's stock, valued at approximately $40,438,000. Upstream Bio comprises 29.0% of Enavate Sciences GP LLC's investment portfolio, making the stock its biggest holding. Enavate Sciences GP LLC owned 4.59% of Upstream Bio as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds also recently modified their holdings of UPB. BNP Paribas Financial Markets purchased a new stake in Upstream Bio in the fourth quarter worth $25,000. US Bancorp DE purchased a new stake in Upstream Bio in the fourth quarter worth $27,000. Legal & General Group Plc purchased a new stake in Upstream Bio in the fourth quarter worth $28,000. Summit Investment Advisors Inc. purchased a new stake in Upstream Bio in the fourth quarter worth $30,000. Finally, Tower Research Capital LLC TRC purchased a new stake in Upstream Bio in the fourth quarter worth $47,000.
Upstream Bio Price Performance
Shares of Upstream Bio stock traded down $0.09 during trading hours on Wednesday, reaching $8.56. The company had a trading volume of 256,299 shares, compared to its average volume of 326,738. Upstream Bio, Inc. has a one year low of $5.14 and a one year high of $29.46. The business has a fifty day simple moving average of $8.06 and a 200 day simple moving average of $13.31.
Upstream Bio (NASDAQ:UPB - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.51) EPS for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.02). The firm had revenue of $0.57 million during the quarter, compared to analysts' expectations of $0.71 million. As a group, equities research analysts forecast that Upstream Bio, Inc. will post -4.3 EPS for the current year.
Upstream Bio Company Profile
(
Free Report)
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
Read More
Before you consider Upstream Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstream Bio wasn't on the list.
While Upstream Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
